With this contracting file whose conditions are established in the specifications, it is intended to cover the use of the medicine included in the file to meet the clinical needs of Osakidetza patients and related centers and which are summarized in the report's memory.

Active substance: efavirenz (DOE) / emtricitabine (DOE) / tenofovir disoproxil (DOE)

Amount of active substance: 600 mg, 200 mg and 245 mg, respectively

Pharmaceutical form: tablet

Packaging conditions: unit dose preferably

Maximum unit price: 2 EUR / tablet (taxes not included)

Number of units planned: 390,000 tablets

Maximum estimated budget: EUR 780,000.00 (first year of contract)